Table 2.
Activity of ceftolozane-tazobactam in non-ESBL and ESBL producing Escherichia coli and Klebsiella pneumoniae isolates resistant to amoxicillin/ clavulanate (AMC), piperacillin/tazobactam (P/T), meropenem (MER) and ciprofloxacin (CIP) in the SMART study (2016 and 2017) in Spain.
| Microorganisms | ESBL (No.) | Antimicrobial | No. (% of resistant isolates) | Ceftolozane-tazobactam | |
|---|---|---|---|---|---|
| Susceptible No. (%) |
Resistant No. (%) |
||||
| Escherichia coli | Negative (318)a | AMCa | 52 (16.3) | 50 (96.1) | 2 (3.9) |
| Positive (29)a | 16 (55.1) | 14 (87.5) | 2 (12.5) | ||
| Negative (1322) | P/T | 85 (6.4) | 78 (91.7) | 7 (8.3) | |
| Positive (125) | 23 (18.4) | 19 (82.6) | 4 (17.4) | ||
| Negative (1322) | MER | 0 (0) | -- | -- | |
| Positive (125) | 0 (0) | -- | -- | ||
| Negative (1322) | CIP | 331 (25) | 325 (98.2) | 6 (1.8) | |
| Positive (125) | 110 (88) | 106 (96.4) | 4 (3.6) | ||
| Klebsiella pneumoniae | Negative (62)a | AMCa | 5 (8.0) | 5 (100) | 0 (0) |
| Positive (19)a | 9 (47.3) | 3 (33.3) | 6 (66.6) | ||
| Negative (397) | P/T | 39 (9.8) | 31 (79.5) | 8 (20.5) | |
| Positive (174) | 129 (74.1) | 32 (24.8) | 97 (75.2) | ||
| Negative (397) | MER | 5 (1.2) | 0 (0) | 5 (100) | |
| Positive (174) | 11 (6.3) | 0 (0) | 11 (100) | ||
| Negative (397) | CIP | 48 (12.0) | 41 (85.4) | 7 (14.6) | |
| Positive (174) | 164 (94.2) | 69 (42.1) | 95 (57.9) | ||
a
AMC: data are only from 2017